The HIV vaccine pipeline, from preclinical to phase III.
Schultz
A M
AM
International AIDS Vaccine Initiative, New York, New York, USA. aschultz@iavi.org
Bradac
J A
JA
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D005822:Genetic Vectors; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology
D016915:AIDS Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins